Treatment of autoimmune disease by immunomodulation through extracorporeal elimination and intravenous immunoglobulin

Borberg, H.; Jiménez, Carlos; Belák, M; Haupt, Walter F.; Späth, Peter

doi:10.1016/0955-3886(94)90173-2

Cited by 8 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Globaffin has been developed for the extracoporeal treatmentof antibody‐mediated diseases, especially autoimmune diseases. Today,the superior performance of IA over plasmapheresis is widely accepted(2,8,9). Moreover, the reductionof plasma components other than Ig, such as coagulation factors,albumin or hormones, is avoided by IA (10,11).…”

Section: Removal Of Immunoglobulins By Globaffinmentioning

confidence: 99%

Peptide Based Adsorbers for Therapeutic Immunoadsorption

Rönspeck¹,

Brinckmann²,

Egner³

et al. 2003

Ther Apher Dial

View full text Add to dashboard Cite

Peptides as ligands for immunoadsorption exhibit several potential advantages over native proteins. Two newly developed adsorbers are based on peptides covalently coupled to sepharose CL-4B. Globaffin is capable of binding immunoglobulins independent from their antigen specificity and thus, applicable in transplant recipients and several antibody mediated autoimmune diseases. Among others, the most important disorders suitable for the treatment with Globaffin are rheumatoid arthritis, systemic lupus erythematosus, and acute renal transplant rejection. Coraffin is a specific adsorber using two linear peptide ligands mimicking epitopes of the beta1-adrenergic receptor, that bind corresponding autoantibodies from patients suffering from idiopathic dilated cardiomyopathy. Specific immunoadsorption has been shown to be beneficial for patients with dilated cardiomyopathy. Coraffin can be used as a new therapeutic option for these patients, who get only limited benefit from medical therapy. Both adsorbers may be combined with all approved apheresis control devices available.

show abstract

Section: Removal Of Immunoglobulins By Globaffinmentioning

confidence: 99%

Peptide Based Adsorbers for Therapeutic Immunoadsorption

Rönspeck¹,

Brinckmann²,

Egner³

et al. 2003

Ther Apher Dial

View full text Add to dashboard Cite

show abstract

“…When myasthenia is serious (myasthenic crisis), plasmapheresis can be used to remove putative antibodies from the circulation. Intravenous immunoglobulins (IVIGs) can also be used to bind the circulating antibodies [2–5]. Both of these treatments have relatively short-lived benefits, which are typically measured in weeks [6].…”

Section: Introductionmentioning

confidence: 99%

Extracorporeal Immunoglobulin Elimination for the Treatment of Severe Myasthenia Gravis

Bláha

Piťha

Bláha

et al. 2010

Journal of Biomedicine and Biotechnology

View full text Add to dashboard Cite

Myasthenia gravis (MG) is a neuromuscular disorder leading to fluctuating muscle weakness and fatigue. Rarely, long-term stabilization is not possible through the use of thymectomy or any known drug therapy. We present our experience with extracorporeal immunoglobulin (Ig) elimination by immunoadsorption (adsorbers with human Ig antibodies). Acetylcholine receptor antibodies (AChRAs) were measured during long-term monitoring (4.7 ± 2.9 years; range 1.1–8.0). A total of 474 samples (232 pairs) were analyzed, and a drop in AChRA levels was observed (P = .025). The clinical status of patients improved and stabilized. Roughly 6.8% of patients experienced clinically irrelevant side effects. The method of Ig elimination by extracorporeal immunoadsorption (IA) is a clinical application of the recent biotechnological advances. It offers an effective and safe therapy for severe MG even when the disease is resistant to standard therapy.

show abstract

Hydrophobic Interaction Chromatography

O'Farrell¹

1998

Springer Protocols Handbooks

View full text Add to dashboard Cite

Treatment of autoimmune disease by immunomodulation through extracorporeal elimination and intravenous immunoglobulin

Cited by 8 publications

References 8 publications

Peptide Based Adsorbers for Therapeutic Immunoadsorption

Peptide Based Adsorbers for Therapeutic Immunoadsorption

Extracorporeal Immunoglobulin Elimination for the Treatment of Severe Myasthenia Gravis

Hydrophobic Interaction Chromatography

Contact Info

Product

Resources

About